Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Ironwood Pharmaceuticals (IRWD) over the last 8 years, with Sep 2025 value amounting to $475,000.

  • Ironwood Pharmaceuticals' Depreciation and Depletion fell 6.31% to $475,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 6.48%. This contributed to the annual value of $2.0 million for FY2024, which is 27.68% up from last year.
  • Ironwood Pharmaceuticals' Depreciation and Depletion amounted to $475,000 in Q3 2025, which was up 1.71% from $467,000 recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Depreciation and Depletion registered a high of $513,000 during Q1 2024, and its lowest value of $270,000 during Q2 2023.
  • In the last 3 years, Ironwood Pharmaceuticals' Depreciation and Depletion had a median value of $485,000 in 2024 and averaged $455,182.
  • In the last 5 years, Ironwood Pharmaceuticals' Depreciation and Depletion crashed by 80.34% in 2021 and then soared by 87.41% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $359,000 in 2021, then dropped by 5.29% to $340,000 in 2022, then skyrocketed by 50.59% to $512,000 in 2023, then dropped by 5.27% to $485,000 in 2024, then fell by 6.31% to $475,000 in 2025.
  • Its Depreciation and Depletion was $475,000 in Q3 2025, compared to $467,000 in Q2 2025 and $479,000 in Q1 2025.